Courtney Flaherty

The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management

The phase 3 ALA-BCC-CT013 study of Ameluz and RhodoLED PDT in sBCC had its last enrolled patient complete a 1-year follow-up visit.

Enfortumab vedotin-efjv plus has received NMPA approval for patients with locally advanced or metastatic urothelial cancer.

Flonoltinib maleate generated rapid clinical benefits, including spleen volume reduction and symptom improvement, for patients with myelofibrosis.

Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

Tarlatamab was granted conditional marketing authorization in the United Kingdom for previously treated extensive-stage small cell lung cancer.

Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.

The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.

Ritu Salani, MD, discusses the role of mirvetuximab soravtansine in ovarian cancer and the need for specialist involvement in ocular toxicity management.

Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations.

Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.

Aaron Gerds, MD, discusses differences in molecular targets, efficacy, and toxicity profiles between available JAK inhibitors in myelofibrosis.

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.